A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said recently as it released its phase 2 trial results.
The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side effects in people aged 56 and over than in younger people — a significant finding given that Covid-19 disproportionately causes severe illness among seniors.
The manufacturers said the vaccine was undergoing larger, more comprehensive phase 3 trials to confirm the results.
Immune responses from vaccines tend to lessen as people get older as the immune system gradually slows with age.
-Courtesy by AFP